0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CCT3- LINC00326 axis regulates hepatocarcinogenic lipid metabolism

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To better comprehend transcriptional phenotypes of cancer cells, we globally characterised RNA-binding proteins (RBPs) to identify altered RNAs, including long non-coding RNAs (lncRNAs).

          Design

          To unravel RBP-lncRNA interactions in cancer, we curated a list of ~2300 highly expressed RBPs in human cells, tested effects of RBPs and lncRNAs on patient survival in multiple cohorts, altered expression levels, integrated various sequencing, molecular and cell-based data.

          Results

          High expression of RBPs negatively affected patient survival in 21 cancer types, especially hepatocellular carcinoma (HCC). After knockdown of the top 10 upregulated RBPs and subsequent transcriptome analysis, we identified 88 differentially expressed lncRNAs, including 34 novel transcripts. CRISPRa-mediated overexpression of four lncRNAs had major effects on the HCC cell phenotype and transcriptome. Further investigation of four RBP-lncRNA pairs revealed involvement in distinct regulatory processes. The most noticeable RBP-lncRNA connection affected lipid metabolism, whereby the non-canonical RBP CCT3 regulated LINC00326 in a chaperonin-independent manner. Perturbation of the CCT3- LINC00326 regulatory network led to decreased lipid accumulation and increased lipid degradation in cellulo as well as diminished tumour growth in vivo.

          Conclusions

          We revealed that RBP gene expression is perturbed in HCC and identified that RBPs exerted additional functions beyond their tasks under normal physiological conditions, which can be stimulated or intensified via lncRNAs and affected tumour growth.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

          This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The Hallmarks of Cancer

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Recognition of RNA N 6 -methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation

              N 6-methyladenosine (m6A) is the most prevalent modification in eukaryotic messenger RNAs (mRNAs) and is interpreted by its readers, such as YTH domain-containing proteins, to regulate mRNA fate. Here we report the insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs; including IGF2BP1/2/3) as a distinct family of m6A readers that target thousands of mRNA transcripts through recognizing the consensus GG(m6A)C sequence. In contrast to the mRNA-decay-promoting function of YTHDF2, IGF2BPs promote the stability and storage of their target mRNAs (e.g., MYC) in an m6A-depedent manner under normal and stress conditions and thus affect gene expression output. Moreover, the K homology (KH) domains of IGF2BPs are required for their recognition of m6A and are critical for their oncogenic functions. Our work therefore reveals a different facet of the m6A-reading process that promotes mRNA stability and translation, and highlights the functional importance of IGF2BPs as m6A readers in post-transcriptional gene regulation and cancer biology.
                Bookmark

                Author and article information

                Journal
                Gut
                Gut
                gutjnl
                gut
                Gut
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                0017-5749
                1468-3288
                October 2022
                12 January 2022
                : 71
                : 10
                : 2081-2092
                Affiliations
                [1 ] departmentDepartment of Microbiology, Tumor, and Cell Biology, Science for Life Laboratory , Karolinska Institute , Stockholm, Sweden
                [2 ] Barts Cancer Institute, Centre for Cancer Cell and Molecular Biology, John Vane Science Centre, Queen Mary University of London , London, UK
                [3 ] departmentComparative Medicine , Karolinska Institute , Stockholm, Sweden
                [4 ] departmentDepartment of Medicine , Karolinska Institute , Stockholm, Sweden
                [5 ] departmentDepartment of Physiology and Pharmacology , Karolinska Institute , Stockholm, Sweden
                Author notes
                [Correspondence to ] Dr Claudia Kutter, Department of Microbiology, Tumor, and Cell Biology, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden; claudia.kutter@ 123456ki.se
                Author information
                http://orcid.org/0000-0002-4438-6756
                http://orcid.org/0000-0001-7132-7172
                http://orcid.org/0000-0002-0757-6681
                http://orcid.org/0000-0002-4226-0009
                http://orcid.org/0000-0003-0892-7460
                http://orcid.org/0000-0002-0632-6808
                http://orcid.org/0000-0003-2834-1512
                http://orcid.org/0000-0001-6256-7107
                http://orcid.org/0000-0001-6691-3396
                http://orcid.org/0000-0002-8586-6502
                http://orcid.org/0000-0002-8047-0058
                Article
                gutjnl-2021-325109
                10.1136/gutjnl-2021-325109
                9484377
                35022268
                0a209f74-7ef1-4cf6-a15e-791e266c28d8
                © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:  https://creativecommons.org/licenses/by/4.0/.

                History
                : 09 May 2021
                : 09 December 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000289, Cancer Research UK;
                Award ID: RCCFEL\100007
                Funded by: Chinese Scholarship Council;
                Award ID: 2016–00189
                Award ID: 2018–00904
                Funded by: FundRef http://dx.doi.org/10.13039/100015652, Barts Charity;
                Award ID: MGU0404
                Funded by: Lillian Sagens & Curt Ericssons research foundation;
                Award ID: 2021-00427
                Funded by: Knut & Alice Wallenberg foundation;
                Award ID: 2017–00358
                Award ID: 2018–00328
                Award ID: 2020-00294
                Award ID: KAW 2016.0174
                Funded by: SNIC;
                Award ID: 2017/7-154
                Funded by: Tornspiran Foundation;
                Award ID: SLS-693561
                Award ID: SLS-694791
                Funded by: FundRef http://dx.doi.org/10.13039/501100005010, Associazione Italiana per la Ricerca sul Cancro;
                Award ID: N/A
                Funded by: Swedish Research Council;
                Award ID: 2019–05165
                Categories
                Hepatology
                1506
                2312
                Original research
                Custom metadata
                unlocked

                Gastroenterology & Hepatology
                lipid metabolism,hepatocellular carcinoma
                Gastroenterology & Hepatology
                lipid metabolism, hepatocellular carcinoma

                Comments

                Comment on this article